Four cardiac hormones cause cytotoxicity of human cancer cells but not of healthy cells

Cancer Therapy

Volumn 8, Issue ISSUE A, 2011, Pages 44-50

  Pi, Guillermo E ^a   Skelton IV, William P ^b   Vesely, David L ^c  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b Duke University   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cardiac hormones; Cytotoxicity; Pancreatic cancer; Prostate cancer

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CARDIAC HORMONE; HORMONE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG; VESSEL DILATOR HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROSTATE ADENOCARCINOMA;

EID: 84865683258     PISSN: 15439135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Brenner BM, Ballerman BJ, Gunning ME, and Zeidel ML (1990) Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70, 665-699.
2. Gower WR Jr, Risch RM, Godellas CV, and Fabri PJ (1994) HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol 30A, 151-161.
3. Niles AL, Moravec RA, Hesselberth E, Scurria MA, Daily WJ, and Riss TL (2007) A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal Biochem 366, 197-206.
4. Stone KR, Mickey DD, Wunderli H, Mickey GH, and Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21, 284-29.
5. Sun Y, Eichelbaum EJ, Wang H, and Vesely DL (2006a) Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26, 3217-3222.
6. Sun Y, Eichelbaum EJ, Wang H, and Vesely DL (2006b) Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 26, 4143-4148.
7. Sun Y, Eichelbaum EJ, Wang H, and Vesely DL (2007a) Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27, 1387-1392
8. Sun Y, Eichelbaum EJ, Wang H, and Vesely DL (2007b) Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27, 3813-3818.
9. Sun Y, Eichelbaum EJ, Lenz A., Skelton WP IV, Wang H, and Vesely DL (2009a) Atrial natriuretic peptide and longacting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 29, 1889-1893.
10. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H, and Vesely DL (2009b) Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 29, 971-975.
11. Sun Y, Eichelbaum EJ, Wang H, and Vesely DL (2009c) Vessel dilator and kaliuretic peptide activate ERK 1/2 kinases in fibroblasts. Horm Metab Res 41, 197-201.
12. Vesely BA, McAfee Q, Gower WR Jr, and Vesely DL (2003) Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33, 998-1005.
13. Vesely BA, Alli AA, Song S, Gower WR Jr, J. Sanchez-Ramos J, and Vesely DL (2005) Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35, 700-710.
14. Vesely DL (2007) Natriuretic hormones. In: The Kidney: Physiology and Pathophysiology, 4th edition. Alpern RJ and Herbert SC (eds.). San Diego, CA: Elsevier/Academic Press, pp 947-977.
15. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL, and Gower WR Jr (2007) Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21, 445-452